Why the study?
Are serum biomarkers (cTnI, cTnT, FABP3) sensitive early indicators of Imatinib-induced myocardial alterations in rats?
Population
Male Sprague-Dawley rats
Comparison
Imatinib 50, 100, or 200 mg/kg orally daily for… vs Water orally daily for 28 days
Design
Preclinical
Follow-up
28 days
Authors
Loading...
Biomarkers may miss low-dose imatinib myocardial lesions; leaves open their sensitivity as early indicators and requires clinical validation.
Are serum biomarkers (cTnI, cTnT, FABP3) sensitive early indicators of Imatinib-induced myocardial alterations in rats?
Cardiac biomarkers (cTnI, cTnT, FABP3) may lack sensitivity as early indicators of Imatinib-induced cardiotoxicity, as structural myocardial damage occurs at lower doses without consistent biomarker elevation.
Herman et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: